ArticleOncology letters2014
Signet ring cell carcinoma of the ampulla of Vater: Immunophenotype and differentiation.
Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Primary pancreatic signet ring cell carcinoma: molecular mechanisms and advances in clinical diagnosis and treatment.World journal of surgical oncology · 2025Review
- Signet ring cell carcinoma of the ampulla of Vater: case series.Oxford medical case reports · 2025Article
- Review
- Article
- Primary Pancreatic Signet Ring Cell Carcinoma: A Case Report and Review of the Literature.Journal of pancreatic cancer · 2021Review
- Signet ring cell cancer of Ampulla of Vater-first ever case reported in a teenager and a review of literature.Rare tumors · 2021Article
- Signet-ring cell carcinoma of the ampulla of Vater: a case diagnosed via repeated biopsies.Clinical journal of gastroenterology · 2020Article
- Prognostic Nomogram for Disease-Specific Survival in Patients with Non-metastatic Ampullary Carcinoma After Surgery.Annals of surgical oncology · 2019Article
- Poorly differentiated adenocarcinoma with signet-ring cells in duodenal papilla: a case report.Surgical case reports · 2017Article
- Characterization of various cell lines from different ampullary cancer subtypes and cancer associated fibroblast-mediated responses.BMC cancer · 2016Article
- Signet Ring Cell Carcinoma of the Ampulla of Vater with Early Development of Bone Metastasis: Case Report and Review of the Rare Malignancy.Journal of gastrointestinal cancer · 2016Review
- Signet ring cell carcinoma of the ampulla of vater: Report of a case and a review of the literature.International journal of surgery case reports · 2015Article
- Signet Ring Cell Carcinoma of the Ampulla of Vater: A Rare Histopathological Variant.Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Signet ring cell carcinoma (SRC) of the ampulla of Vater is extremely rare and the histogenesis remains unknown. In the present study, to investigate the immunohistochemical phenotypes, discuss the histological origin and evaluate the correlation between the immunohistochemical phenotypes and survival of ampullary SRC patients, a retrospective review was conducted. This included all ampullary carcinoma patients treated at The First Affiliated Hospital, College of Medicine, Zhejiang University, and was performed over a five-year period between 2008 and 2012. Eight resected ampullary SRC specimens were examined histopathologically and immunohistochemically, using cytokeratin (CK) and mucin (MUC) immunohistochemical phenotypes. Of all 162 patients with ampullary lesions, eight cases (4.9%) of ampullary SRC were identified. Immunohistochemical analyses of the eight cases revealed the positive expression of CK7 in five, CK19 in seven, CK20 in one, MUC1 in five, MUC2 in three, caudal-related homeobox transcription factor 2 in one, MUC5AC in seven and MUC6 in four of the eight cases, while loss of E-cadherin and β-catenin was observed in four of the eight cases. According to immunohistochemical classification, ampullary SRC can be classified into four subtypes: Intestinal (I), pancreatobiliary (PB), gastric and mixed types (composed of I mucosa lining and PB epithelium). Patients with the I-type ampullary SRC demonstrated a more favorable prognosis than that of patients with the PB-type ampullary SRC. Additionally, patients with ampullary SRC of I or PB type with gastric differentiation may have a worse prognosis than others. The coexpression of the E-cadherin/β-catenin complex may also indicate poor prognosis in PB-type ampullary SRC. In conclusion, the clinical five-year follow-up of the patients with pure SRC was more positive than that of those with I-, PB-, gastric- or mixed-type ampullary SRC. The coexpression of the E-cadherin/β-catenin complex may present a poor prognosis in the PB type of ampullary SRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.